The uric acid to HDL-C ratio: one number, two opposing signals
Uric Acid / HDL-C blood testing measures two related signals and expresses them together as a ratio. Uric acid (urate) is the end product of purine breakdown, formed mainly in the liver and carried in the bloodstream before most of it is cleared by the kidneys. HDL-C is the cholesterol cargo within high-density lipoproteins, particles made in the liver and intestine that circulate in blood. Putting them together as the uric acid–to–HDL cholesterol ratio (UHR) summarizes these opposing biological currents in one number.
What it reflects: uric acid tends to mirror metabolic and oxidative pressure in the body (oxidative stress, low-grade inflammation, purine turnover), while HDL particles contribute to protective tasks such as cholesterol efflux and reverse cholesterol transport (RCT), along with antioxidant and anti-inflammatory actions at the vessel lining (endothelium). The UHR therefore captures the balance between pro-oxidant, metabolism-linked load and the counterbalancing, vessel-protective capacity of HDL. In practical terms, it offers a compact view of how your system is managing purine metabolism, lipid transport, and redox/inflammatory tone within the circulation.
Why pair urate with HDL cholesterol
The uric acid/HDL-C ratio links two powerful signals of metabolic health: uric acid, the end-product of purine metabolism that shifts from antioxidant to pro-oxidant at higher levels, and HDL cholesterol, which supports reverse cholesterol transport and vascular repair. Together, this ratio reflects the balance between oxidative/inflammatory load and lipid-clearing capacity, touching the heart, kidneys, liver, joints, and blood vessels.
The uric acid/HDL-C ratio divides serum uric acid by HDL cholesterol. It reflects the balance between purine-derived oxidative load and HDL's cholesterol transport and antioxidant activity, linking to insulin sensitivity, vascular tone, liver and kidney health, and overall cardiometabolic risk.
Big picture: this ratio integrates purine metabolism, renal excretion, oxidative stress, and lipoprotein transport. Interpreted alongside uric acid, HDL, triglycerides, glucose, blood pressure, and liver markers, it helps profile long-term cardiometabolic and renal risk.
High versus low UHR: what each pattern signals
There is no universal clinical reference range for this ratio. In general, lower values are considered more favorable because they pair lower uric acid with higher HDL. Ratios tend to be lower in women (especially premenopausal) and in youth, and often rise with age and central adiposity. Being in range suggests balanced purine production, renal handling, and HDL-mediated lipid traffic, supporting metabolic stability and control of low-grade inflammation.
Low values usually reflect lower uric acid and/or higher HDL-C, indicating lower oxidative load, adequate renal urate excretion, and more effective HDL transport. System-wide this aligns with better insulin sensitivity and endothelial function. People typically feel well; this pattern aligns with better insulin sensitivity and endothelial health. Children and early pregnancy are typically lower. Exceptionally low values, driven by very low uric acid, are uncommon and can accompany rare renal tubular transport conditions or severe undernutrition, but most individuals are asymptomatic.
High values usually reflect higher uric acid and/or lower HDL-C. Physiology includes increased purine turnover, reduced renal urate clearance, and insulin resistance with fewer or less functional HDL particles. Physiologically, this aligns with insulin resistance, adipose inflammation, endothelial dysfunction, and hepatic fat accumulation. Clinically, it associates with gout flares, uric acid kidney stones, hypertension, chronic kidney disease, and atherosclerotic risk. Ratios often rise in men, in postmenopausal women, and in teens with obesity; in pregnancy, a rising ratio late in gestation can track with higher uric acid and adverse placental vascular states.
Hydration, diuretics, and assay choices that influence UHR
Fasting state, hydration, acute illness, and medications influence interpretation. Thiazide/loop diuretics and low-dose aspirin raise urate; niacin raises urate and HDL; SGLT2 inhibitors lower urate. HDL assay methods vary. There are no standardized decision thresholds, so compare with lab references and follow trends over time.
FAQs
Uric Acid / HDL-C testing calculates a ratio from serum uric acid and HDL-C results, summarizing pro-inflammatory and protective signals tied to cardiometabolic, gout, and kidney stone risk.
It can flag risk earlier than single markers, add context to gout and stone risk, and strengthen assessment of insulin resistance, fatty liver, hypertension, and atherosclerotic risk while providing clear feedback on lifestyle changes.
Test regularly for trend tracking—for example, with routine labs or every few months when changing diet, alcohol intake, training, sleep, or weight.
Diet (especially fructose-sweetened drinks), alcohol (beer and spirits), hydration, body weight and visceral fat, insulin resistance, training status, sleep, stress, medications, and underlying conditions such as kidney or thyroid issues.
Some lipid panels require fasting; follow the instructions provided with your lab order to helps support accurate HDL-C and uric acid measurements.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Li, Z., Liu, Q., Yao, Z., Zhang, L., Yu, M., & Guo, J. (2024). The serum uric acid-to-high-density lipoprotein cholesterol ratio is a predictor for all-cause and cardiovascular disease mortality: A cross-sectional study. Frontiers in Endocrinology, 15, 1417485. https://doi.org/10.3389/fendo.2024.1417485
- Gherghina, M. E., Peride, I., Tiglis, M., Neagu, T. P., Niculae, A., & Checherita, I. A. (2022). Uric acid and oxidative stress—Relationship with cardiovascular, metabolic, and renal impairment. International Journal of Molecular Sciences, 23(6), 3188. https://doi.org/10.3390/ijms23063188
- Guo, Z. G., Li, C., Zhong, J. K., Tu, Y., & Xie, D. (2012). Laboratory investigation of dysfunctional HDL. Chemistry and Physics of Lipids, 165(1), 32-37. https://doi.org/10.1016/j.chemphyslip.2011.10.005
- Feingold, K. R. (2024). Introduction to lipids and lipoproteins. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
- McLaughlin, T., Abbasi, F., Cheal, K., Chu, J., Lamendola, C., & Reaven, G. (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine, 139(10), 802-809. https://doi.org/10.7326/0003-4819-139-10-200311180-00007






































.avif)
